2018 was undoubtedly one of the most important years ever for biopharma, setting records for valuations and dealmaking. But a paper published in January called some of that exuberance into question, noting that many startups over the years have managed to become unicorns – with valuations of $1 billion or more – despite having little or no published, peer-reviewed data.
{iframe}https://medcitynews.com/2019/03/whats-behind-sky-high-valuations-of-biopharma-startups/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=70952779&_hsenc=p2ANqtz-98wxJPu0RkBsf1FPLbw-gpfuJKMqT22zeA6n9diuozJL6CINL7eSTC_ba4UK0QIj7k_j9AOYynit52r8sfmHzk6AePOA&_hsmi=70952779{/iframe}